Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma
Barata P, Tangen C, Plets M, Thompson I, Narayan V, George D, Heng D, Shuch B, Stein M, Gulati S, Tretiakova M, Tripathi A, Bjarnason G, Humphrey P, Adeniran A, Vaishampayan U, Alva A, Zhang T, Cole S, Lara P, Lerner S, Balzer-Haas N, Pal S. Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. Journal Of Clinical Oncology 2024, 42: 3911-3916. PMID: 39255440, PMCID: PMC11575905, DOI: 10.1200/jco.24.00767.Peer-Reviewed Original ResearchAdvanced papillary renal cell carcinomaPapillary renal cell carcinomaRenal cell carcinomaOverall survivalCell carcinomaProlonged progression-free survivalLack of survival benefitProgression-free survivalRandomized phase IIMedian follow-upPrimary end pointOpen-label trialOverall survival analysisCrizotinib armMedian OSSurvival benefitClinical trial updateNo significant differenceCabozantinibTreatment armsSunitinibFollow-upClinical trialsSavolitinibCrizotinibCorrelative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial
Plimack E, Tangen C, Plets M, Kokate R, Xiu J, Nabhan C, Ross E, Grundy E, Choi W, Dinney C, Lee I, Fong M, Lucia M, Daneshmand S, Theodorescu D, Goldkorn A, Lerner S, Flaig T, McConkey D. Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial. European Urology 2024, 86: 297-300. PMID: 39003201, PMCID: PMC11416320, DOI: 10.1016/j.eururo.2024.06.018.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerCisplatin-based chemotherapyNeoadjuvant chemotherapyBladder cancerTumor samplesNeoadjuvant cisplatin-based chemotherapyResponse to NACClinical assessmentDose-dense methotrexateTiming of cystectomyPathological complete responseClinical trials of chemotherapyTrials of chemotherapyNational clinical trialNeoadjuvant gemcitabineBladder preservationComplete responseTumor specimensSurgical specimensMulticenter trialPatient selectionTreatment armsGene panelChemotherapyGene mutations